64.97 USD
+0.01 (+0.02%)
64.99 USD
+0.02 (+0.03%)
Overall ALPN gets a fundamental rating of 4 out of 10. We evaluated ALPN against 525 industry peers in the Biotechnology industry. While ALPN has a great health rating, there are worries on its profitability. ALPN is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- ALPN had negative earnings in the past year.
- ALPN had a negative operating cash flow in the past year.
- ALPN had negative earnings in each of the past 5 years.
- In the past 5 years ALPN reported 4 times negative operating cash flow.
1.2 Ratios
- ALPN has a better Return On Assets (-9.86%) than 87.99% of its industry peers.
- With an excellent Return On Equity value of -11.07%, ALPN belongs to the best of the industry, outperforming 90.05% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -9.86% | ||
| ROE | -11.07% | ||
| ROIC | N/A |
ROA(3y)-16.1%
ROA(5y)-29.01%
ROE(3y)-27.88%
ROE(5y)-54.08%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for ALPN so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- ALPN does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for ALPN has been increased compared to 1 year ago.
- There is no outstanding debt for ALPN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- ALPN has an Altman-Z score of 64.87. This indicates that ALPN is financially healthy and has little risk of bankruptcy at the moment.
- ALPN has a Altman-Z score of 64.87. This is amongst the best in the industry. ALPN outperforms 98.46% of its industry peers.
- There is no outstanding debt for ALPN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 64.87 |
ROIC/WACCN/A
WACC9.11%
2.3 Liquidity
- ALPN has a Current Ratio of 9.56. This indicates that ALPN is financially healthy and has no problem in meeting its short term obligations.
- ALPN's Current ratio of 9.56 is fine compared to the rest of the industry. ALPN outperforms 74.96% of its industry peers.
- A Quick Ratio of 9.56 indicates that ALPN has no problem at all paying its short term obligations.
- ALPN has a Quick ratio of 9.56. This is in the better half of the industry: ALPN outperforms 75.13% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 9.56 | ||
| Quick Ratio | 9.56 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 60.82% over the past year.
- Looking at the last year, ALPN shows a very strong growth in Revenue. The Revenue has grown by 118.80%.
- The Revenue has been growing by 141.96% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)60.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)118.8%
Revenue growth 3Y84.73%
Revenue growth 5Y141.96%
Sales Q2Q%-25.09%
3.2 Future
- The Earnings Per Share is expected to decrease by -13.31% on average over the next years. This is quite bad
- Based on estimates for the next years, ALPN will show a very strong growth in Revenue. The Revenue will grow by 33.81% on average per year.
EPS Next Y-157.63%
EPS Next 2Y-70.39%
EPS Next 3Y-54.78%
EPS Next 5Y-13.31%
Revenue Next Year-56.25%
Revenue Next 2Y-32.39%
Revenue Next 3Y-34.72%
Revenue Next 5Y33.81%
3.3 Evolution
- Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for ALPN. In the last year negative earnings were reported.
- Also next year ALPN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- ALPN's earnings are expected to decrease with -54.78% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-70.39%
EPS Next 3Y-54.78%
5. Dividend
5.1 Amount
- ALPN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ALPINE IMMUNE SCIENCES INC / ALPN FAQ
What is the fundamental rating for ALPN stock?
ChartMill assigns a fundamental rating of 4 / 10 to ALPN.
What is the valuation status for ALPN stock?
ChartMill assigns a valuation rating of 0 / 10 to ALPINE IMMUNE SCIENCES INC (ALPN). This can be considered as Overvalued.
Can you provide the profitability details for ALPINE IMMUNE SCIENCES INC?
ALPINE IMMUNE SCIENCES INC (ALPN) has a profitability rating of 2 / 10.
What is the financial health of ALPINE IMMUNE SCIENCES INC (ALPN) stock?
The financial health rating of ALPINE IMMUNE SCIENCES INC (ALPN) is 8 / 10.
What is the earnings growth outlook for ALPINE IMMUNE SCIENCES INC?
The Earnings per Share (EPS) of ALPINE IMMUNE SCIENCES INC (ALPN) is expected to decline by -157.63% in the next year.